This article has been updated with additional comment from the company's earnings conference call.

NEW YORK (GenomeWeb) – OpGen reported after the close of the market on Tuesday that its second quarter revenues dropped 42 percent year over year.

For the three months ended June 30, the firm reported total revenues of $703,210, down from $1.2 million in Q2 2016. Product sales fell to $681,127 from $1.0 million in the year-ago quarter, while lab services revenues fell to $15,850 from $29,674, and collaboration revenues sank to $6,233 from $125,000.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Rare gene mutations are guiding the search for drugs to manage chronic pain without opioids, according to CNBC.

The new Francis Crick Institute building can get too noisy for some researchers to concentrate, according to the Guardian.

CBS News reports that there are still many vacancies at the White House Office of Science and Technology Policy, but that it's uncertain whether they will be filled.

In Nucleic Acids Research this week: pipeline to analyze and visualize bacterial genomes, database of global set of human genomes, and more.